Want to see HK:2179 full AI Analyst Report?
Jiangsu Recbio Technology Co., Ltd. Class H (2179) AI Stock Analysis
Jiangsu Recbio Technology Co., Ltd. Class H
(HKEX:2179)
The score is primarily constrained by persistent losses, substantial cash burn, rising leverage, and negative valuation support. Bearish technical positioning further weakens the outlook, while oversold momentum provides only limited offset.
Jiangsu Recbio Technology Co., Ltd. Class H (2179) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 1.81B
- Dividend Yield
- ―
- Average Volume (3M)
- 9,425
- Price to Earnings (P/E)
- -4.4
- Beta (1Y)
- 0.55
- Revenue Growth
- -82.46%
- EPS Growth
- 41.19%
- Country
- Hong Kong
- Employees
- 466
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Jiangsu Recbio Technology Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company primarily engaged in the pioneering research, development, and eventual market introduction of subunit vaccines throughout the People's Republic of China. A significant portion o...
How the Company Makes Money
The company makes money primarily through (1) commercialization of its vaccine/biologics products (when approved), generating revenue from product sales to customers in the healthcare supply chain; and (2) out-licensing and/or collaboration arrangeme...
Jiangsu Recbio Technology Co., Ltd. Class H Financial Statement Overview
Summary
Very weak performance: persistent and worsening net losses, negative gross profit, heavy operating cash burn, rising leverage, and deeply negative ROE. Positive equity and manageable debt provide limited support.
Income Statement
12Very NegativeBalance Sheet
38NegativeCash Flow
25Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.29M | 12.40M | 27.00M | 30.38M | 5.33M | 6.20M |
| Gross Profit | -47.33M | -91.46M | 15.95M | 22.34M | 5.33M | 6.20M |
| EBITDA | -357.03M | -483.72M | -491.04M | -553.85M | -834.14M | -590.00M |
| Net Income | -477.06M | -594.59M | -562.39M | -571.96M | -719.20M | -657.56M |
Balance Sheet | ||||||
| Total Assets | 1.60B | 1.76B | 1.94B | 2.19B | 2.31B | 1.92B |
| Cash, Cash Equivalents and Short-Term Investments | 187.51M | 351.99M | 448.31M | 837.76M | 1.33B | 1.18B |
| Total Debt | 672.99M | 638.75M | 889.10M | 650.79M | 282.63M | 76.72M |
| Total Liabilities | 1.10B | 1.06B | 1.41B | 1.12B | 656.53M | 245.92M |
| Stockholders Equity | 497.98M | 706.14M | 529.32M | 1.07B | 1.66B | 1.67B |
Cash Flow | ||||||
| Free Cash Flow | -505.26M | -601.50M | -636.66M | -862.18M | -888.04M | -710.79M |
| Operating Cash Flow | -445.83M | -502.64M | -464.82M | -638.07M | -579.54M | -472.92M |
| Investing Cash Flow | -78.43M | 35.43M | -279.04M | 9.42M | -378.43M | 68.70M |
| Financing Cash Flow | 596.88M | 499.77M | 218.06M | 275.27M | 839.44M | 1.23B |
Jiangsu Recbio Technology Co., Ltd. Class H Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2179, the sentiment is Negative. The current price of 4.00 is below the 20-day moving average (MA) of 4.13, below the 50-day MA of 4.55, and below the 200-day MA of 4.78, indicating a bearish trend. The MACD of -0.20 indicates Negative momentum. The RSI at 38.81 is Neutral, neither overbought nor oversold. The STOCH value of 81.99 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2179.
Jiangsu Recbio Technology Co., Ltd. Class H Peers Comparison
Overall Rating
HK:699870Outperform
HK:269664.6Neutral
HK:187741.25Neutral
HK:187541Neutral
HK:219739Underperform- HK:217938Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:6998 | 70Outperform | HKD 3.26B | 4.48 | 10.99% | ― | 1417.68% | 660.14% |
| HK:2696 | 65Neutral | HKD 26.75B | 26.18 | 20.41% | ― | 32.63% | 8.74% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:1877 | 41Neutral | HKD 30.07B | -69.15 | -7.23% | ― | 35.82% | 54.40% |
| HK:1875 | 41Neutral | HKD 2.56B | -12.79 | -26.14% | ― | -51.10% | -2384.76% |
| HK:2197 | 39Underperform | HKD 1.62B | 1.61 | -64.89% | ― | -99.15% | ― |
| HK:2179 | 38Underperform | HKD 2.49B | -4.41 | -79.24% | ― | -82.46% | 41.19% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2179 | Jiangsu Recbio Technology Co., Ltd. Class H | 4.00 | -2.99 | -42.78% | |
| HK:6998 | Genor Biopharma Holdings Limited | 1.62 | -1.51 | -48.24% | |
| HK:1875 | TOT BIOPHARM International Co. Ltd. | 3.31 | 1.38 | 71.50% | |
| HK:1877 | Shanghai Junshi Biosciences Co., Ltd. Class H | 15.26 | -11.44 | -42.85% | |
| HK:2197 | Clover Biopharmaceuticals Ltd. | 1.25 | -0.99 | -44.20% | |
| HK:2696 | Shanghai Henlius Biotech, Inc. Class H | 49.06 | -20.04 | -29.00% |
Jiangsu Recbio Technology Co., Ltd. Class H Corporate Events
Recbio Completes Phase III Trial of Novel Shingles Vaccine REC610 in China
Jiangsu Recbio Technology has completed a Phase III clinical trial of its independently developed novel adjuvanted recombinant shingles vaccine REC610 in China and obtained the trial summary report. The study showed that REC610, designed to prevent h...
Jiangsu Recbio Announces Board-Level Resignation and New Authorised Representative
Jiangsu Recbio Technology Co., Ltd. announced that executive director and board secretary Mr. Wei Qifang has resigned from his roles, including authorised representative and joint company secretary, effective August 25, 2026, citing personal reasons...
Jiangsu Recbio Sets Out Board Composition and Committee Structure
Jiangsu Recbio Technology Co., Ltd., a Hong Kong-listed joint stock company based in Jiangsu Province, has detailed the composition of its board of directors, which includes a non-executive chairman, two executive directors, several non-executive dir...
Jiangsu Recbio Clarifies Board Composition and Committee Leadership
Jiangsu Recbio Technology Co., Ltd., a joint stock biopharmaceutical company based in Jiangsu Province and listed in Hong Kong as a Class H issuer, operates with a multi-tier board comprising executive, non-executive and independent non-executive dir...
Recbio Advances Shingles and HPV Vaccines as Interim Loss Narrows
Jiangsu Recbio Technology Co., Ltd. reported significant R&D progress in the first half of 2026, led by its novel adjuvanted recombinant shingles vaccine REC610, which has completed Phase III enrollment and dosing in China and advanced to the mar...
Jiangsu Recbio Formalizes H Share Full Circulation with Amended Articles
Jiangsu Recbio Technology Co., Ltd. has amended its Articles of Association following the completion of its H Share Full Circulation plan, which converted 141,953,489 previously unlisted shares into H shares. As a result, the company now reports a to...
Jiangsu Recbio Sets Board Meeting to Review 2026 Interim Results and Consider Dividend
Jiangsu Recbio Technology Co., Ltd., a Hong Kong–listed biopharmaceutical company incorporated in the PRC, has a board structure that includes a non-executive chairman, multiple executive and non-executive directors, and several independent non...
Jiangsu Recbio Flags Narrowed First-Half Loss as Clinical Spend Eases
Jiangsu Recbio Technology has warned of a continued loss for the first half of 2026, although its estimated net loss has narrowed significantly compared with a year earlier. The improvement reflects the completion of heavy clinical trial investment o...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 17, 2026